Literature DB >> 17629845

High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase.

Antonella Bisio1, Alessandra Mantegazza, Elena Urso, Annamaria Naggi, Giangiacomo Torri, Christian Viskov, Benito Casu.   

Abstract

Heparanase is an endo-beta-D-glucuronidase that cleaves the heparan sulfate chains of heparan sulfate proteoglycans and is implicated in angiogenesis and metastasis. With the aim of establishing a simple and reliable method for studying the susceptibility of heparin/heparan sulfate oligosaccharides to be cleaved by heparanase, an on-line ion pair reversed-phase high-performance liquid chromatographic/electrospray ionization mass spectrometric method was set up. The method works in the micromolar range of concentration and does not require derivatization of the substrate or of the products. It is based on mass identification of oligosaccharide fragments generated by heparanase and their quantification with reference to an internal heparin disaccharide standard. Substrates were (1) the synthetic pentasaccharides GlcN (NS,6S) - GlcA - GlcN (NS,3S,6S) - IdoA (2S) - GlcN (NS,6S) - OMe (AGA*IA (M)) and GlcN (NS,6S) - GlcA - GlcN (NS,6S) - IdoA (2S) - GlcN (NS,6S) - OMe (AGAIA (M)), corresponding to the heparin/heparan sulfate active site for antithrombin, and to the same sequence devoid of the 3- O-sulfate group in the central glucosamine, respectively; and (2) two natural heparin octasaccharides containing the AGA*IA sequence in different locations along the chain. The two pentasaccharides exhibited a higher susceptibility to heparanase cleavage with respect to the octasaccharides. The commercial availability of AGA*IA (M) makes it an ideal substrate to determine the specific activity of heparanase preparations. The present method could also be used for rapid screening of potential heparanase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17629845     DOI: 10.1055/s-2007-982079

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  8 in total

1.  Analysis of glycosaminoglycan-derived, precolumn, 2-aminoacridone-labeled disaccharides with LC-fluorescence and LC-MS detection.

Authors:  Nicola Volpi; Fabio Galeotti; Bo Yang; Robert J Linhardt
Journal:  Nat Protoc       Date:  2014-02-06       Impact factor: 13.491

Review 2.  Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.

Authors:  Benito Casu; Annamaria Naggi; Giangiacomo Torri
Journal:  Matrix Biol       Date:  2010-04-21       Impact factor: 11.583

3.  The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.

Authors:  K Dredge; E Hammond; K Davis; C P Li; L Liu; K Johnstone; P Handley; N Wimmer; T J Gonda; A Gautam; V Ferro; I Bytheway
Journal:  Invest New Drugs       Date:  2009-04-09       Impact factor: 3.850

4.  Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides.

Authors:  Anna Alekseeva; Benito Casu; Giangiacomo Torri; Sabrina Pierro; Annamaria Naggi
Journal:  Anal Biochem       Date:  2012-11-29       Impact factor: 3.365

Review 5.  Heparin and heparan sulfate: analyzing structure and microheterogeneity.

Authors:  Zachary Shriver; Ishan Capila; Ganesh Venkataraman; Ram Sasisekharan
Journal:  Handb Exp Pharmacol       Date:  2012

6.  Heparanase as an Additional Tool for Detecting Structural Peculiarities of Heparin Oligosaccharides.

Authors:  Anna Alekseeva; Elena Urso; Giulia Mazzini; Annamaria Naggi
Journal:  Molecules       Date:  2019-12-02       Impact factor: 4.411

Review 7.  The Development of Assays for Heparanase Enzymatic Activity: Towards a Gold Standard.

Authors:  Mohit Chhabra; Vito Ferro
Journal:  Molecules       Date:  2018-11-14       Impact factor: 4.411

Review 8.  From Cancer to COVID-19: A Perspective on Targeting Heparan Sulfate-Protein Interactions.

Authors:  Mohit Chhabra; Gareth G Doherty; Nicholas W See; Neha S Gandhi; Vito Ferro
Journal:  Chem Rec       Date:  2021-06-19       Impact factor: 6.935

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.